U.S. to resume J&J COVID-19 vaccinations despite rare clot risk

The government uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot, out of nearly 8 million people given the J&J shot

U.S. health officials lifted an 11-day using Johnson & Johnson's single-dose shot, after scientific advisers decided its benefits outweigh a rare risk of blood clot. The government uncovered 15 vaccine recipients who developed a highly , out of nearly 8 million people given the J&J shot. All were women, most under age 50. Three died, and seven remain hospitalized.